Cochlear Of Australia Vows Return Of Recalled Hearing Implants To Market
This article was originally published in PharmAsia News
Executive Summary
Australia’s Cochlear vowed to get its recalled hearing implants back on the market, but would not say when.
You may also be interested in...
FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?
Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.
Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Need a specific report? 1000+ reports available
Buy Reports